G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Yun Jung | - |
dc.contributor.author | Shin, Dongyun | - |
dc.contributor.author | Lee, Ju-Yeun | - |
dc.date.available | 2020-02-28T17:45:51Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-04 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12744 | - |
dc.description.abstract | With growing needs for new antidiabetic drugs which are safe and effective alone or in combination with existing drugs, G-protein coupled receptor 40 (GPR40) has drawn a considerable attention as a potential therapeutic target for type 2 diabetes. As GPR40 agonist may offer advantages to commonly used agents, by acting ambient glucose dependent manner which mechanistically leads to reduced risk of developing hypoglycemia. Since deorphanization in 2003, development of small molecule GPR40 agonists has been spurred by several research groups. There are a number of lead molecules targeting GPR40, and among these molecules TAK-875 (full agonist) and AMG 837 (partial agonist) advanced into clinical stage. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.relation.isPartOf | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.subject | STIMULATED INSULIN-SECRETION | - |
dc.subject | FATTY-ACIDS | - |
dc.subject | GLUCOSE | - |
dc.subject | IMPROVES | - |
dc.subject | TAK-875 | - |
dc.subject | GPR40 | - |
dc.subject | CANAGLIFLOZIN | - |
dc.subject | INHIBITOR | - |
dc.subject | MELLITUS | - |
dc.subject | TARGET | - |
dc.title | G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000333695800002 | - |
dc.identifier.doi | 10.1007/s12272-013-0283-3 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.37, no.4, pp.435 - 439 | - |
dc.identifier.kciid | ART001901962 | - |
dc.identifier.scopusid | 2-s2.0-84897554321 | - |
dc.citation.endPage | 439 | - |
dc.citation.startPage | 435 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 37 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Shin, Dongyun | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | GPR40 agonist | - |
dc.subject.keywordAuthor | Antidiabetics | - |
dc.subject.keywordAuthor | Type 2 diabetes mellitus | - |
dc.subject.keywordPlus | STIMULATED INSULIN-SECRETION | - |
dc.subject.keywordPlus | FATTY-ACIDS | - |
dc.subject.keywordPlus | GLUCOSE | - |
dc.subject.keywordPlus | IMPROVES | - |
dc.subject.keywordPlus | TAK-875 | - |
dc.subject.keywordPlus | GPR40 | - |
dc.subject.keywordPlus | CANAGLIFLOZIN | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | MELLITUS | - |
dc.subject.keywordPlus | TARGET | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.